

Corporate Seminar

J Japanese Session / **E** English Session

11-Oct (Fri) 11:20–12:05

JLS1-1 **Cutting edge of High-risk AML treatment –How to change launch of CPX-351–**

[No.1 Kyoto International Conference Center 1F Main Hall]

- Chair** Hitoshi Kiyoi (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine)
- Speaker** Yosuke Masamoto (Department of Cell Therapy and Transplantation, University of Tokyo Hospital)
- Sponsor** Nippon Shinyaku Co., Ltd.

ELS1-2

[No.2 Kyoto International Conference Center 2F Room A]

- Chair** Akihiko Gotoh (Department of Hematology, Tokyo Medical University)
- Impact of molecular response in Polcythemia Vera**
- Speaker** Keita Kirito (Department of Hematology and Oncology, University of Yamanashi)
- Treatment strategy for PV : The Ropeg-IFN era**
- Speaker** Rami Komrokji (Malignant Hematology Department, Moffitt Cancer Center, US)
- Sponsor** PharmaEssentia Japan KK

JLS1-3 **Rebalancing therapy for Hemophilia**

[No.3 Kyoto International Conference Center 1F Sakura]

- Chair** Midori Shima (Nara Medical University)
- Speaker** Tadashi Matsushita (Department of Clinical Laboratory and Department of Blood Transfusion Service, Nagoya University Hospital)
- Sponsor** Novo Nordisk Pharma Ltd.

ELS1-4 **CAR T treatment in DLBCL – Recent advances and findings –**

[No.4 Kyoto International Conference Center 1F Room D]

- Chair** Miki Ando (Juntendo University School of Medicine)
- Speaker** Caron Jacobson (Dana-Farber Cancer Institute)
- Sponsor** Gilead Sciences K.K.

LS1-5 Current status and future perspectives of AML treatment in the era of targeted therapy

[No.5 Kyoto International Conference Center 1F Room E]

- Chair** Noriko Doki (Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital)
- Speaker** Kenichi Matsuoka (Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School)
- Sponsor** DAIICHI SANKYO COMPANY, LIMITED.

LS1-6 Understanding the hidden power of EZH2 inhibitors – their potential as a new precision medicine.

[No.6 Kyoto International Conference Center 2F Room B-1]

- Chair** Yoshiaki Ogawa (Tokai University School of Medicine Department of Hematology & Oncology)
- Speaker** Tomoki Ito (Kansai Medical University First Department of Internal Medicine)
- Sponsor** Eisai Co., Ltd.

LS1-7 How to use BTK inhibitors in CLL: updates

[No.7 Kyoto International Conference Center 2F Room B-2]

- Chair** Hirokazu Nagai (NHO Nagoya Medical Center)
- Speaker** Ritsuro Suzuki (Shimane University)
- Sponsor** AstraZeneca K.K.

LS1-10 Future ITP treatment strategy based on pathology –The potential and future of the anti-FcRn fragment antibody VYVGART–

[No.10 Kyoto International Conference Center 2F Room K]

- Chair** Kenji Yokoyama (Department of Hematology / Oncology, Tokai University Hachioji Hospital)
- Speaker** Hisashi Kato (Department of Blood Transfusion, Osaka University Hospital)
- Sponsor** argenx Japan K.K.

LS1-11 Management of fungal infection in patients with hematological malignancies

[No.11 Kyoto International Conference Center 1F Room C-1]

- Chair** Masashi Sawa (Department of Hematology, Oncology Anjo Kosei Hospital, Aichi, Japan)
- Speaker** Yasuo Mori (Department of Hematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan)
- Sponsor** MSD K.K.

LS1-12 The role of Thiotepa in autologous hematopoietic stem cell transplantation for malignant lymphoma – experiences in Kansai Electric Power Hospital –

[No.12 Kyoto International Conference Center 1F Room C-2]

- Chair** Momoko Nishikori (Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan)
- Speaker** Katsuhiko Io (Department of Hematology, Kansai Electric Power Hospital)
- Sponsor** Sumitomo Pharma Co.,Ltd.

LS1-13 Heterogeneity of Self-Renewal Capacity in Human Hematopoietic Stem Cells

[No.13 Kyoto International Conference Center 1F Room F]

- Chair** Jun Suzuki (Institute for Advanced Study, WPI-iCeMS, Kyoto University)
- Speaker** Masanori Miyanishi (Hematopoietic Stem Cell Biology and Medical Innovation (HSCBMI), Department of Pediatrics, Kobe University Graduate School of Medicine)
- Sponsor** Nippon Becton Dickinson Co.,Ltd.

LS1-15 The potential for the treatment of relapsed/refractory PTCL: Based on clinical experience with darinaparsin

[No.15 Kyoto International Conference Center 1F Room H]

- Chair** Noriko Fukuhara (Department of Hematology, Tohoku University Graduate School of Medicine)
- Speaker** Daisuke Ikeda (Department of Hematology and Oncology, Okayama University Hospital)
- Sponsor** Nippon Kayaku Co.,Ltd.

LS1-16 New Dimension of Diagnosis and Treatment for MPN

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

- Chair** Hideo Harigae (Department of Hematology, Tohoku University Graduate School of Medicine)
- Differential diagnosis of eosinophilia and Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions**
- Speaker** Yuka Sugimoto (Department of Hematology and Oncology, Mie University Graduate School of Medicine)
- Pemigatinib for FGFR1-BCR fusion gene-positive leukemia: mechanism of action and countermeasures for hyperphosphatemia**
- Speaker** Daisuke Ogiya (Department of Hematology and Oncology, Tokai University School of Medicine)
- Sponsor** Incyte Japan G.K.

■LS1-17 Treatment strategies for multiple myeloma

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

- Chair** Chiaki Nakaseko (International University of Health and Welfare)
Speaker Go Yamamoto (Toranomon Hospital)
Sponsor Fuji Pharma Co., Ltd.

■LS1-18 New' but old' Plan-B for preventing toxicities of high-dose methotrexate

[No.18 The Prince Kyoto Takaragaike B2F Gold Room]

- Chair** Dai Maruyama (Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
Speaker Eisei Kondo (Department of Hematology, Kawasaki Medical School)
Sponsor OHARA Pharmaceutical Co.,Ltd.

12-Oct (Sat) 11:20–12:05

■LS2-1 Treatment Strategies for Transplant-Ineligible Multiple Myeloma

[No.1 Kyoto International Conference Center 1F Main Hall]

- Chair** Kazutaka Sunami (Dept. of Hematology, NHO Okayama Medical Center)

Unlocking the Potential of Daratumumab-Containing Regimens as Initial Treatment: Insights from Evidence and Daily Clinical Practice

- Speaker** Yuichi Horigome (Dept. of Hematology, Kitasato University Graduate School of Medicine Sciences)

The Importance of Daratumumab Treatment Continuation and Infection Management

- Speaker** Tomohiko Kamimura (Dept. of Hematology, Harasanshin Hospital)
Sponsor Janssen Pharmaceutical K.K.

■LS2-2 Treatment strategy for DLBCL in 2024 “Remember Polivy once in a while”

[No.2 Kyoto International Conference Center 2F Room A]

- Chair** Shigeru Kusumoto (Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital)
Speaker Ken Ohmachi (Tokai University, School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology)
Sponsor Chugai Pharmaceutical Co., Ltd.

■LS2-3 The forefront of R/R DLBCL treatment: How has our practice changed after the launch of Epcoritamab?

[No.3 Kyoto International Conference Center 1F Sakura]

- Chair** Koichi Akashi (Department of Medicine and Biosystemic Science, Faculty of Medicine, Kyushu University)
Speaker Suguru Fukuhara (Department of Hematology, National Cancer Center Hospital)
Sponsor Genmab K.K. / AbbVie GK

LS2-4 An approach to the treatment of anemia in lower risk MDS

[No.4 Kyoto International Conference Center 1F Room D]

- Chair** Mineo Kurokawa (Department of Hematology and Oncology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo)
- Speaker** Guillermo Garcia-Manero (Department of Leukemia, The University of Texas MD Anderson Cancer Center)
- Sponsor** Bristol-Myers Squibb K.K.

LS2-5 Recent Advances in IST and Transplantation for Patients with Aplastic Anemia

[No.5 Kyoto International Conference Center 1F Room E]

- Chair** Takehiko Mori (Department of Hematology, Tokyo Medical and Dental University)
- Speaker** Yasushi Onishi (Department of Hematology, Tohoku University Hospital)
- Sponsor** Pfizer Japan Inc.

LS2-6 The therapeutic strategy for RRMM with the 4 Sarclisa®-based regimens.

[No.6 Kyoto International Conference Center 2F Room B-1]

- Chair** Chihiro Shimazaki (JCHO Kyoto Kuramaguchi Medical Center)
- Speaker** Teruhito Takakuwa (Department of Hematology Wakakusa-Daiichi Hospital)
- Speaker** Takashi Ikeda (Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center)
- Sponsor** Sanofi K.K.

LS2-7 Progress in PNH treatment: Emergence of new anti-complement drugs

[No.7 Kyoto International Conference Center 2F Room B-2]

- Chair** Takahiro Suzuki (Department of Hematology, Kitasato University School of Medicine)
- Speaker** Yasutaka Ueda (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)
- Sponsor** Alexion Pharma GK

LS2-10 Diagnosis and treatment evolution of myelofibrosis

[No.10 Kyoto International Conference Center 2F Room K]

- Chair** Kazuhiko Ikeda (Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine)
- Speaker** Takeshi Kondo (Blood Disorders Center, Aiiiku Hospital)
- Sponsor** GlaxoSmithKline

LS2-11 Molecular mechanism and treatment strategy of DLBCL

[No.11 Kyoto International Conference Center 1F Room C-1]

- Chair** Yasuhito Terui (Department of Hematology, Saitama Medical University Hospital)
- Speaker** Daisuke Ennishi (Center for Comprehensive Genomic Medicine, Okayama University Hospital)
- Sponsor** Kyowa kirin Co.,Ltd

LS2-12 The Importance of Class Switching in the Treatment of Multiple Myeloma

[No.12 Kyoto International Conference Center 1F Room C-2]

- Chair** Nobuyuki Takayama (Department of Hematology, Kyorin University Faculty of Medicine, Tokyo, Japan)
- Emerging role of carfilzomib in the era of cellular immunotherapy for multiple myeloma**
- Speaker** Nobuhiro Tsukada (Department of Hematology, Japanese Red Cross Medical Center, Japan)
- Sponsor** ONO PHARMACEUTICAL CO.,LTD.

LS2-15

[No.15 Kyoto International Conference Center 1F Room H]

- Chair** Hidesaku Asakura (Department of Hematology, Kanazawa University Hospital)
- Treatment strategies based on DIC classification**
- Speaker** Hidesaku Asakura (Department of Hematology, Kanazawa University Hospital)
- The evidence of rTM treatment in DIC associated with hematological malignancies**
- Speaker** Noriaki Kawano (Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital)
- Sponsor** Asahi Kasei Pharma Corporation

LS2-16 The Option of Oral Monotherapy: Fabhalta, a Complement Factor B Inhibitor, Opens a New World of Treatment for PNH

Live Recording On-demand

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

- Chair** Shinji Nakao (Japanese Red Cross Ishikawa Blood Center)
- Speaker** Toshio Kitawaki (Department of Hematology, Kyoto University Hospital)
- Sponsor** Novartis Pharma K.K.

■LS2-17 Current Status and Future of GVHD Treatment

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

Chair Shuichi Taniguchi (Federation of National Public Service Personnel Mutual Aid Association Hamanomachi Hospital)

Various symptoms and treatment challenges of chronic GVHD

Speaker Hideki Nakasone (Division of Emerging Medicine for Integrated Therapeutics (EMIT) Center for Molecular Medicine, Jichi Medical University / Division of Hematology, Jichi Medical University Saitama Medical Center)

Sponsor Meiji Seika Pharma Co., Ltd.

■LS2-18 Treatment strategies to prevent relapse after transplantation in *FLT3* gene mutation-positive AML

[No.18 The Prince Kyoto Takaragaike B2F Gold Room]

Chair Hiroki Yamaguchi (Department of Hematology Nippon Medical School)

Speaker Takashi Toya (Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital)

Sponsor Astellas Pharma Inc.

13-Oct (Sun) 11 : 50 – 12 : 35

■LS3-1 Future Perspectives on Frontline Therapy in CML and Treatment-free remission

[No.1 Kyoto International Conference Center 1F Main Hall]

Chair Tomoiku Takaku (Hematology, Saitama Medical University Hospital)

Speaker Dennis Dong Hwan Kim (Medical Oncology and Hematology, Princess Margaret Cancer Center, Ontario, Canada)

Sponsor Novartis Pharma K.K. Medical Affairs

■LS3-2 Long-term treatment strategies for Unfit AML based on our experience with VEN+AZA combination therapy

[No.2 Kyoto International Conference Center 2F Room A]

Chair Toshihiro Miyamoto (Department of Hematology, Kanazawa University Hospital)

Speaker Jun Ando (Department of Hematology, Juntendo University Graduate School of Medicine)

Sponsor AbbVie GK

LS3-3 The importance of achieving well-being for multiple myeloma patients and the significance of maintenance therapy

[No.3 Kyoto International Conference Center 1F Sakura]

Chair Yasushi Takamatsu (Division of Medical Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University)

Treatment strategy to achieve patient well-being in multiple myeloma

Speaker Shigeki Ito (Hematology and Oncology, Department of Internal medicine, Iwate Medical University School of Medicine)

Sponsor Takeda Pharmaceutical Company Limited

LS3-4 Latest updates in treatment of PNH from real-world evidence of C3 inhibitor

[No.4 Kyoto International Conference Center 1F Room D]

Chair Masatoshi Sakurai (Division of Hematology, Department of Medicine, Keio University School of Medicine)

Speaker Richard Kelly (Leeds Teaching Hospitals NHS Trust)

Sponsor Swedish Orphan Biovitrum Japan / Asahi Kasei Pharma

LS3-5 Optimal treatment strategies for acute lymphoblastic leukemia in children and adults

[No.5 Kyoto International Conference Center 1F Room E]

Chair Motohiro Kato (Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan)

Advances in asparaginase for treatment of ALL

Speaker Mio Yano (Department of Pediatrics, Kyoto City Hospital, Kyoto, Japan)

Optimizing adult ALL treatment with asparaginase

Speaker Koji Nagafuji (Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan)

Sponsor NIHON SERVIER CO.,LTD.

LS3-6 Treatment strategy for ITP and clinical positioning of fostamatinib

[No.6 Kyoto International Conference Center 2F Room B-1]

Chair Masataka Kuwana (Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine)

Speaker Nichola Cooper (Department of Immune Haematology, Imperial College London)

Sponsor KISSEI PHARMACEUTICAL CO., LTD.

LS3-7 Insights of Bendamustine from North Japan Hematology Study Group: for the new-era in follicular lymphoma treatment

[No.7 Kyoto International Conference Center 2F Room B-2]

- Chair** Akihito Yonezawa (Department of Hematology, Kokura Memorial Hospital)
Speaker Minoru Kanaya (Blood Disorders Center, Aiiiku Hospital)
Sponsor SymBio Pharmaceuticals Limited

LS3-10 Bacterial Infection and Antimicrobial therapy in hematological malignancies

[No.10 Kyoto International Conference Center 2F Room K]

- Chair** Junko Takida (Dept. of Pediatrics, Graduate School of Medicine, Kyoto University)
Speaker Yusuke Koizumi (Dept. of Clinical Infectious Diseases, Infection Control and Prevention Wakayama Medical University)
Sponsor Shionogi & Co.,Ltd.

LS3-11 Advances and prospects in the treatment of chronic GVHD –Introduction of ECP in Japan–

[No.11 Kyoto International Conference Center 1F Room C-1]

- Chair** Masayuki Hino (Department of Hematology, Osaka Metropolitan University Graduate School of Medicine)
Speaker Tatsunori Goto (Department of Transfusion, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital)
Sponsor Mallinckrodt Pharma K.K.

LS3-12 Ph+ Leukemia : Latest Perspectives on Diagnosis and Treatment

[No.12 Kyoto International Conference Center 1F Room C-2]

- Chair** Komei Kubo (Department of Hematology, Aomori Prefectural Central Hospital)
Speaker Koji Sasaki (Department of Leukemia The University of Texas MD Anderson Cancer Center, Houston TX, U.S.A.)
Sponsor Otsuka Pharmaceutical Co., Ltd.

LS3-13 TDM in hematology using novel medical diagnostic device LM1010 automated analyzer

[No.13 Kyoto International Conference Center 1F Room F]

- Chair** Shinya Kimura (Division of Hematology, Respiratory Medicine and Oncology, Saga University)
Speaker Masatomo Miura (Department of Pharmacokinetics, Akita University Graduate School of Medicine)
Sponsor Hitachi High-Tech Corporation

■LS3-15 Positioning of Pirtobrutinib in MCL treatment

【No.15 Kyoto International Conference Center 1F Room H】

- Chair** Koji Kato (Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science)
- Speaker** Kazuyuki Shimada (Department of Hematology, Nagoya University Hospital)
- Sponsor** Nippon Shinyaku Co., Ltd.

■LS3-16 Update on the Treatment for Iron Deficiency Anemia

~From the Perspective of Iron and Life Evolution on the Earth~

【No.16 The Prince Kyoto Takaragaike 1F Royal Room】

- Chair** Norio Komatsu (Department of Hematology, Juntendo University School of Medicine)
- Speaker** Masayoshi Kobune (Department of Medical Oncology and Department of Hematology, Sapporo Medical University)
- Sponsor** Medical Affairs Department, Torii Pharmaceutical Co., Ltd.

■LS3-17 Leukemia Genomics and MRD: FLT3 Molecularly Targeted Therapeutic Biomarker

【No.17 The Prince Kyoto Takaragaike B1F Rose Room】

- Chair** Hideaki Nakajima (Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine)
- Speaker** Yosuke Minami (Department of Hematology, National Cancer Center Hospital East)
- Sponsor** Invivoscribe/LabPMM GK

■LS3-18 Role of Immunoglobulin Replacement Therapy in the management of infection after allo-HCT

【No.18 The Prince Kyoto Takaragaike B2F Gold Room】

- Chair** Takahiro Fukuda (Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan)
- Speaker** Shigeo Fuji (Department of Hematology, Osaka International Cancer Institute, Osaka, Japan)
- Sponsor** CSL Behring K.K.

11-Oct (Fri) 16:20–17:05

ES1-1 Diagnosis and Treatment of Myelofibrosis and Polycythemia Vera

[No.1 Kyoto International Conference Center 1F Main Hall]

Chair Kazuya Shimoda (Division of Hematology, Diabetes and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki)

Advances in the Treatment of Myelofibrosis

Speaker Katsuto Takenaka (Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine)

Treatment Strategies for Polycythemia Vera

Speaker Shuichi Ota (Department of Hematology, Sapporo Hokuyu Hospital)

Sponsor Novartis Pharma K.K.

ES1-2 CAR-T Therapy in LBCL:

Treatment Strategies Based on the Product Characteristics

[No.2 Kyoto International Conference Center 2F Room A]

Chair Takanori Teshima (Department of Hematology, Hokkaido University Faculty of Medicine)

Speaker Jun Kato (Division of Hematology, Keio University School of Medicine)

Sponsor Bristol-Myers Squibb K.K.

ES1-3 Latest treatment strategies for AA and ITP and positioning of Revolade

Live Recording On-demand

[No.3 Kyoto International Conference Center 1F Sakura]

Chair Kinuko Mitani (Dokkyo Medical University)

The Frontline of Aplastic Anemia Treatment in the Era of TPO-RA

Speaker Hirohito Yamazaki (Division of Medical Safety, Kanazawa University Hospital)

Perspective of ITP treatments: New possibilities of eltrombopag

Speaker Hirokazu Kashiwagi (Department of Hematology and Oncology, Osaka University Graduate School of Medicine/Osaka Red Cross Blood Center)

Sponsor Novartis Pharma K.K.

ES1-4 New Era Treatment Strategies for Multiple Myeloma

[No.4 Kyoto International Conference Center 1F Room D]

Chair Yoichi Imai (Department of Hematology and Oncology, Dokkyo Medical University)

Evolving Therapies in Multiple Myeloma

Speaker Satoshi Yoshihara (Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine)

Technological Innovations in Antibody Drugs

Speaker Kouhei Tsumoto (Department of Bioengineering School of Engineering, The University of Tokyo)

Sponsor Janssen Pharmaceutical K.K., Medical Affairs Division

ES1-5 Current situation of caplacizumab use for immune thrombotic thrombocytopenic purpura

[No.5 Kyoto International Conference Center 1F Room E]

- Chair** Yasunori Ueda (Department of Hematology, Kurashiki Central Hospital)
- Speaker** Hideo Yagi (Department of Hematology and Oncology, Nara Prefecture General Medical Center)
- Sponsor** Sanofi K.K.

ES1-6 Current strategies in the treatment of follicular lymphoma

[No.6 Kyoto International Conference Center 2F Room B-1]

- Chair** Naoki Hosen (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)
- Speaker** Shinichi Makita (National Cancer Center Hospital)
- Sponsor** Chugai Pharmaceutical Co., Ltd. / Nippon Shinyaku Co., Ltd.

ES1-7 Current treatment strategy for peripheral T-cell lymphomas and the role of Brentuximab vedotin

[No.7 Kyoto International Conference Center 2F Room B-2]

- Chair** Ilseung Choi (Department of Hematology and Cell Therapy, NHO Kyushu Cancer Center)
- Speaker** Nobuhiko Yamauchi (Japanese Foundation for Cancer Research, Cancer Institute Hospital, Department of Hematology Oncology)
- Sponsor** Takeda Pharmaceutical Company Limited

ES1-10 Management of invasive fungal infection in hematological malignancies

— Focusing on targeted therapy for aspergillosis, candidiasis and mucormycosis —

[No.10 Kyoto International Conference Center 2F Room K]

- Chair** Shinsuke Takagi (Department of Hematology, Center for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital)
- Speaker** Shun-ichi Kimura (Division of Hematology, Jichi Medical University Saitama Meical Center)
- Sponsor** Sumitomo Pharma Co., Ltd.

ES1-11 A New Era in the Treatment of Acquired Hemophilia A —Expectations for New Therapeutic Agents—

[No.11 Kyoto International Conference Center 1F Room C-1]

- Chair** Kagehiro Amano (Department of Laboratory Medicine, Tokyo Medical University)
- Speaker** Yoshinobu Seki (Department of Hematology, Niigata University Medical & Dental Hospital)
- Sponsor** Takeda Pharmaceutical Company Limited

■ES1-12 Characteristics of Higher-risk MDS

[No.12 Kyoto International Conference Center 1F Room C-2]

- Chair** Yasushi Miyazaki (Atomic Bomb Disease Institute, Nagasaki University)
- Speaker** Yasuhiro Nannya (The institute of Medical Science, The University of Tokyo)
- Sponsor** AbbVie GK

■ES1-13 A new treatment strategy for PNH –the potential of C3 inhibitors–

[No.13 Kyoto International Conference Center 1F Room F]

- Chair** Kaichi Nishiwaki (Oncol and Hematol, Jikei University Kashiwa)
- Speaker** Yasuyoshi Morita (Hematol and Rheumatol, Kindai University Faculty of Medicine)
- Sponsor** Asahi Kasei Pharma Corporation

■ES1-15 Diagnosis of Hematological Malignancies based on Guidelines

[No.15 Kyoto International Conference Center 1F Room H]

- Chair** Koji Izutsu (Department of Hematology, National Cancer Center Hospital)
- AML and MDS: Understanding of the new International Classifications**
- Speaker** Kaoru Tohyama (Department of Medical Technology, Kawasaki University of Medical Welfare)
- Diagnosis of Hematological Malignancies based of Genomic Profiling**
- Speaker** Masashi Sanada (Department of Advanced Diagnosis, Clinical Research Center, NHO Nagoya Medical Center)
- Sponsor** Otsuka Pharmaceutical Co., Ltd.

■ES1-16 Practical management of Elranatamab treatment: Clinical trials and real-world case studies

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

- Chair** Keisuke Kataoka (Division of Hematology, Department of Medicine, Keio University School of Medicine/Division of Molecular Oncology, National Cancer Center Research Institute)
- Speaker** Taku Kikuchi (Department of Hematology, Japanese Red Cross Medical Center)
- Sponsor** Pfizer Japan Inc.

■ES1-17 Pathophysiology and Novel treatment of chronic GVHD

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

- Chair** Yoshinobu Maeda (Department of Hematology, Oncology and Respiratory, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)
- Speaker** Yoshihiro Inamoto (Department of BMT and Cellular Therapy, Fujita Health University)
- Sponsor** Meiji Seika Pharma Co.,Ltd.

ES1-18 The Importance of Institutional Collaboration to improve CAR T-cell therapy outcomes

[No.18 The Prince Kyoto Takaragaike B2F Gold Room]

- Chair** Kentaro Fukushima (Hematology and Oncology, Osaka University Graduate School of Medicine)
Speaker Yu Yagi (Medical Oncology, Tokyo Metropolitan Komagome Hospital)
Sponsor Gilead Sciences K.K.

12-Oct (Sat) 17:10–17:55

ES2-1 Expert Guidance on Therapeutic Strategies for Relapsed/Refractory Myeloma

[No.1 Kyoto International Conference Center 1F Main Hall]

- Chair** Shinsuke Iida (Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Aichi, Japan)
- The Importance of Immune Reconstitution in Multiple Myeloma Treatment ~ How to Use Pomalidomide-Enhanced Antibody Therapy ~**
- Speaker** Hideto Tamura (Division of Hematology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan)
- Evolving Treatment Strategies for Sequencing Immune-based Therapies**
- Speaker** Doris K. Hansen (H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida)
- Sponsor** Bristol-Myers Squibb K.K.

ES2-2 fungal infection management in the new era

[No.2 Kyoto International Conference Center 2F Room A]

- Chair** Satoshi Takahashi (Division of Clinical Precision Research Platform, Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo)
- TIPs for the management of fungal infections when using novel molecular target drugs**
- Speaker** Takahide Ara (Department of Hematology, Hokkaido University Hospital, Sapporo, Japan)
- Critical Drug Interactions with Antifungal Agents in Patients with Acute Leukemia and Transplants**
- Speaker** Junya Kanda (Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan)
- Sponsor** ASAHI KASEI PHARMA CORPORATION

ES2-3 The Signaling Change in CML –New Treatment Strategy for Deep Molecular Response–

[No.3 Kyoto International Conference Center 1F Sakura]

- Chair** Akifumi Takaori-Kondo (Kyoto University Hospital)
- Speaker** Naoto Takahashi (Akita University Graduate School of Medicine, Dept. of Hematology, Nephrology and Rheumatology)
- Sponsor** Novartis Pharma K.K.

**ES2-4 Update on the treatment of Acquired Hemophilia Treatment
- What is changing with emicizumab -**

[No.4 Kyoto International Conference Center 1F Room D]

- Chair** Hidekazu Nishikii (Department of Hematology, Institute of Medicine, University of Tsukuba, Japan)
Speaker Kenichi Ogiwara (Department of Pediatrics, Nara Medical University)
Sponsor Chugai Pharmaceutical Co., Ltd.

ES2-5 Novel therapeutic strategies against CLL based on genetics and molecular biology

[No.5 Kyoto International Conference Center 1F Room E]

- Chair** Itaru Matsumura (Department of Hematology and Rheumatology, Kindai University Faculty of Medicine)
Speaker Yoshikane Kikushige (Center for Cellular and Molecular Medicine, Kyushu University Hospital)
Sponsor AbbVie GK

**ES2-6 Primary Central Nervous System Lymphoma:
Treatment Challenges and Future Perspectives**

[No.6 Kyoto International Conference Center 2F Room B-1]

- Chair** Naohiro Sekiguchi (Department of Hematology, National Hospital Organization Disaster Medical Center)
The current status and future prospects of primary CNS lymphoma
Speaker Lakshmi Nayak (The Center for CNS Lymphoma within the Center for Neuro-Oncology, Dana-Farber Cancer Institute, Neurology at Harvard Medical School)
Sponsor ONO PHARMACEUTICAL CO.,LTD.

ES2-7 Updates in AML 2024 with a focus on Menin as a therapeutic target

[No.7 Kyoto International Conference Center 2F Room B-2]

- Chair** Takahiro Yamauchi (Department of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan)
Speaker Naval G. Daver (Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, TX, USA)
Sponsor Sumitomo Pharma Co., Ltd.

ES2-10 Team Approach for Treatment of Hematologic Malignancies

[No.10 Kyoto International Conference Center 2F Room K]

- Chair** Makoto Murata (Department of Hematology, Shiga University of Medical Science)
Speaker Yasushi Hiramatsu (Hematology / Oncology, Japanese Red Cross Society Himeji Hospital)
Sponsor Takeda Pharmaceutical Company Limited

**ES2-11 Pembrolizumab and Novel Immunotherapies for PMBCL and cHL
~ The Latest Evidence and AE Management~**

[No.11 Kyoto International Conference Center 1F Room C-1]

- Chair** Tatsu Shimoyama (Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)
- Speaker** Junichiro Yuda (Department of Hematology and Experimental Therapeutics, National Cancer Center Hospital East)
- Sponsor** MSD K.K.

ES2-12 Treatment strategies for WM/LPL based on evidence and clinical experience

[No.12 Kyoto International Conference Center 1F Room C-2]

- Chair** Hirotohi Kamata (Department of Hematology, Kitasato University School of Medicine)
- Clinical characteristics and therapeutic strategies of WM/LPL**
- Speaker** Daisuke Kaji (Department of Hematology, Toranomon Hospital)
- Ibrutinib plus Rituximab for a patient with Waldenstrom Macroglobulinemia and mutations in MYD88 and CXCR4**
- Speaker** Yukinori Nakamura (Third Department of Internal Medicine, Yamaguchi University Hospital, Ube, Japan.)
- Sponsor** Janssen Pharmaceutical K.K.

ES2-13 Update on the Pathophysiology and Treatment of Aplastic Anemia

[No.13 Kyoto International Conference Center 1F Room F]

- Chair** Motoshi Ichikawa (Department of Hematology, NTT Medical Center Tokyo)
- Speaker** Kohei Hosokawa (Department of Hematology, Kanazawa University Hospital)
- Sponsor** Kyowa kirin Co.,Ltd

Live Recording On-demand

**ES2-15 Learning about the “Current Status” of Treatment and Society of Intractable Diseases in the Field of Hematology
~The Forefront of Diagnosis, Treatment and Communication~**

[No.15 Kyoto International Conference Center 1F Room H]

- Chairs** Norimitsu Kadowaki (Department of Internal Medicine, Faculty of Medicine, Kagawa University)
Mamoru Ichikawa (READYFOR, Inc/Faculty of Medicine, Hiroshima University)
- “Current” and “Future” Status of Intractable Diseases from the Perspective of Hematologists**
- Speaker** Norimitsu Kadowaki (Department of Internal Medicine, Faculty of Medicine, Kagawa University)
- Social Changes Surrounding Intractable Diseases ~Communication~**
- Speaker** Mamoru Ichikawa (READYFOR, Inc/Faculty of Medicine, Hiroshima University)
- Sponsor** Alexion Pharma GK

ES2-16 Achieving Well-being and Addressing Unmet Needs in Multiple Myeloma

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

Chair Masahiro Abe (Department of Hematology, Kawashima Hospital)

The Frontline of Multiple Myeloma Treatment: Addressing Unmet Needs and the Path Forward

Speaker Mitsuhiro Itagaki (Division of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital)

Sustainable Multiple Myeloma Treatment and the Realization of Well-being

Speaker Shin-ichi Fuchida (Department of Hematology, JCHO Kyoto Kuramaguchi Medical Center)

Sponsor Medical Affairs Department, Takeda Pharmaceutical Company Limited

ES2-17 Cold agglutinin disease: various pathophysiology, diagnosis and management

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

Chair Jun Yamanouchi (Department of Transfusion Medicine and Cell Therapy, Ehime University Hospital)

Speaker Hideho Wada (Department of Hematology, Kawasaki Medical School)

Sponsor Sanofi K.K.

ES2-18 The role of Besponsa in transplant-ineligible relapsed/refractory ALL

[No.18 The Prince Kyoto Takaragaike B2F Gold Room]

Chair Shingo Yano (Division of Clinical Oncology / Hematology, Department of Internal Medicine, The Jikei University School of Medicine)

Speaker Hitoshi Hanamoto (Hematology of Kindai University Nara Hospital)

Sponsor Pfizer Japan Inc.

12-Oct (Sat) 7:30-8:15

MS2-1 Immune-based Therapies in multiple myeloma: a new frontier on the road to cure

[No.1 Kyoto International Conference Center 1F Main Hall]

Chair Emiko Sakaida (Department of Hematology, Chiba University Hospital, Chiba, Japan)

The Significance of the IMiDs Sequence as a Treatment Option

Speaker Nobuhiko Uoshima (Department of Hematology, Japanese Red Cross Kyoto Daini Hospital)

How to Integrate BCMA-Targeting Therapies in RRMM Treatment Strategies

Speaker Tadao Ishida (Japanese Red Cross Medical Center Department of Hematology / Myeloma-Amyloidosis Center)

Sponsor Bristol-Myers Squibb K.K.

**MS2-2 Future treatment strategies for hemophilia A
~Positioning of High Sustained Factor~**

[No.2 Kyoto International Conference Center 2F Room A]

- Chair** Ei Kinai (Department of Laboratory Medicine, Tokyo Medical University)
Speaker Keiji Nogami (Department of Pediatrics, Nara Medical University)
Sponsor Sanofi K.K.

MS2-3 Future B-ALL treatment strategy

[No.3 Kyoto International Conference Center 1F Sakura]

- Chair** Yoshikiyo Ito (Department of Hematology, Imamura General Hospital)
Speaker Takahiro Shima (Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences)
Sponsor Amgen K.K., Medical Affairs / Astellas Pharma Inc., Medical Affairs

MS2-4 Frailty, Fitness, Frontline therapy in Multiple Myeloma

[No.4 Kyoto International Conference Center 1F Room D]

- Chair** Shuji Ozaki (Dept. of Hematology, Tokushima Prefectural Central Hospital)
Speaker Amrita Krishnan (Judy and Bernard Briskin Multiple Myeloma Center Hematology/Hematopoietic Cell Transplantation City of Hope Cancer Center)
Sponsor Janssen Pharmaceutical K.K.

**MS2-5 Emerging Therapies for Relapsed/Refractory ATL and PTCL:
Prospects for Novel Treatments**

[No.5 Kyoto International Conference Center 1F Room E]

- Chair** Kisato Nosaka (Cancer Center, Kumamoto University Hospital)
Speaker Makoto Yoshimitsu (Graduate School of Medical and Dental Sciences, Department of Hematology and Rheumatology, Kagoshima University)
Sponsor DAIICHI SANKYO COMPANY, LIMITED.

**MS2-6 Treatment Strategies for Waldenström Macroglobulinemia/
Lymphoplasmacytic Lymphoma**

[No.6 Kyoto International Conference Center 2F Room B-1]

- Chair** Motoko Yamaguchi (Department of Hematological Malignancies, Mie University Graduate School of Medicine)
**Treatment Strategies for LPL/WM
- Consider from Evidence and Real-world Clinical Practice -**
Speaker Masuho Saburi (Department of Hematology, Oita Prefectural Hospital)
Sponsor ONO PHARMACEUTICAL CO.,LTD.

■MS2-7 The new approach to the treatment of PNH with PIASKY

[No.7 Kyoto International Conference Center 2F Room B-2]

- Chair** Takayuki Ikezoe (Department of Hematology, Fukushima Medical University)
- Speaker** Michihiro Uchiyama (Division of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan)
- Sponsor** Chugai Pharmaceutical Co., Ltd.

■MS2-11 Efforts for hematology treatment system through multidisciplinary collaboration

[No.11 Kyoto International Conference Center 1F Room C-1]

- Chair** Ayako Arai (Department of Hematology & Oncology, St. Marianna University School of Medicine, Kawasaki, Japan)
- Pharmacist intervention and its role in CML treatment**
- Speaker** Tetsuya Wako (Department of Pharmacy, Nippon Medical School Hospital, Bunkyo-ku, Japan)
- Latest CML Treatment: Expanding Options and Drug Information necessary for Patient Decision Making**
- Speaker** Satoshi Wakita (Department of Hematology, Nippon Medical School Hospital, Bunkyo-ku, Japan)
- Sponsor** Novartis Pharma K.K.

■MS2-12 Latest Perspectives on Congenital Coagulation Disorders

[No.12 Kyoto International Conference Center 1F Room C-2]

- Chair** Masanori Matsumoto (Department of Hematology, Nara Medical University)
- Treatment of von Willebrand disease**
- Speaker** Masahiro Takeyama (Division of Hemophilia, National Hospital Organization, Osaka National Hospital)
- Challenges and novel treatment in management of congenital thrombotic thrombocytopenic purpura**
- Speaker** Kazuya Sakai (Department of Blood Transfusion Medicine, Nara Medical University)
- Sponsor** Takeda Pharmaceutical Company Limited

■MS2-13 Treatment Strategies for Hematologic Diseases Based on the Omicron Strain Nationwide Epidemiological Survey

[No.13 Kyoto International Conference Center 1F Room F]

- Chair** Fujita Hiroyuki (Department of Hematology, Saiseikai Yokohama Nanbu Hospital)
- Speaker** Okamoto Akinao (Fujita Health University Hospital, Department of Hematology)
- Sponsor** AstraZeneca K.K.

■MS2-15 Current Status and Future of PTCL Treatment

[No.15 Kyoto International Conference Center 1F Room H]

Chair Kazuhito Yamamoto (Aichi Cancer Center)

Approach to patients with PTCL refractory to first-line therapy

Speaker Katsuhiko Miura (Department of Hematology & Oncology / Tumor Center, Nihon University Itabashi Hospital)

Sponsor Meiji Seika Pharma Co., Ltd.

■MS2-16

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

Chair Junya Kuroda (Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science)

AITL and regulatory T cells through data science

Speaker Mamiko Sakata-Yanagimoto (Department of Hematology, Tsukuba University)

Denileukin diftitox therapy for relapsed refractory PTCL

Speaker Tatsuro Jo (Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital)

Sponsor Eisai Co., Ltd.

■MS2-17 Suggestions for Hemophiliacs to Live Happily for More Than 80 Years

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

Chair Yoshiyuki Ogawa (Gunma University, Department of Hematology)

Speaker Yushi Chikasawa (Tokyo Medical University, Department of laboratory Medicine)

Sponsor CSL Behring K.K.

■MS2-18 CMV Management after hematopoietic stem cell transplantation

[No.18 The Prince Kyoto Takaragaike B2F Gold Room]

Chair Kazuhiro Ikegame (Department of Hematopoietic Stem Cell Transplantation Center, Aichi Medical University, Aichi, Japan)

Speaker Naoki Kurita (Department of Hematology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan)

Sponsor MSD K.K.

13-Oct (Sun) 8:00—8:45

■MS3-1 To improve NRM in allogeneic HSCT: Reaffirming the importance of CMV management

[No.1 Kyoto International Conference Center 1F Main Hall]

Chair Hisayuki Yokoyama (Division of Hematology and Cell Therapy, Department of Third Internal Medicine, Yamagata University Faculty of Medicine)

Speaker Hisashi Yamamoto (Department of Hematology, Toranomon Hospital)

Sponsor Takeda Pharmaceutical Company Ltd. Japan Medical Office

MS3-2 Prevention of Shingles in Hematologic Diseases

[No.2 Kyoto International Conference Center 2F Room A]

How to manage varicella zoster virus reactivation after allogeneic hematopoietic stem cell

Chair Yoshinobu Kanda (Division of Hematology, Department of Medicine, Jichi Medical University)

Zoster and Other Vaccinations in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Recipient

Speaker Keiji Okinaka (National Cancer Center Hospital East Division of Infection Diseases National Cancer Center Hospital Division of Hematopoietic Stem Cell Transplantation)

Sponsor GlaxoSmithKline

MS3-3 Guiding the Revival of Kymriah through Industry-Academia Collaboration: Innovations to Maximize Living Cell Therapy

[No.3 Kyoto International Conference Center 1F Sakura]

Chair Hideki Goto (Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital)

Speaker Yasuyuki Arai (Center for Research and Application of Cellular Therapy, Kyoto University Hospital, Kyoto, Japan)

Sponsor Novartis Pharma K.K.

MS3-4 Reviewing the evidences for ibrutinib in CLL

[No.4 Kyoto International Conference Center 1F Room D]

Chair Jun Takizawa (Department of Hematology, Endocrinology and Metabolism Niigata University Faculty of Medicine)

Speaker Sadao Aoki (Hematology Division, Faculty of Medical Technology, Niigata University of Pharmacy and Medical and Life Sciences)

Sponsor Janssen Pharmaceutical K.K.

MS3-5 How to utilize Sarclisa® in 2nd line therapy considered from basic and clinical perspectives.

[No.5 Kyoto International Conference Center 1F Room E]

Chair Kenshi Suzuki (Adviser of myeloma / AL amyloid unit, Japanese Red Cross Medical Center)

Speaker Keichiro Mihara (Fujita Health University International Gene and Cell therapy Department of Translational Research/Department of Cellular Immunotherapy for Cancer)

Speaker Kentaro Serizawa (Department of Hematology and Rheumatology Faculty of Medicine, Kindai University)

Sponsor Sanofi K.K.

■MS3-6 Considering the Multifaceted Value in Myeloma Treatment

[No.6 Kyoto International Conference Center 2F Room B-1]

Chair Hiroshi Handa (Gunma University Graduate School of Medicine, Department of Hematology)

What is the medicoeconomic value of SC formulation?

Speaker Ataru Igarashi (Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, the University of Tokyo)

Continuous Treatment Strategy for Multiple Myeloma – Work-Style Reform with Daratumumab Therapy –

Speaker Kazuhito Suzuki (The Division of Clinical Oncology–Hematology, Department of Internal Medicine, Jikei University School of Medicine)

Sponsor Janssen Pharmaceutical K.K.

■MS3-7 Treatment Strategies and Future Perspectives in Classical Hodgkin Lymphoma

[No.7 Kyoto International Conference Center 2F Room B-2]

Chair Kenichi Ishizawa (Department of Health Science, School of Health Sciences, Tohoku Fukushi University)

Immunotherapy in classical Hodgkin lymphoma: the current status and future prospects.

Speaker Daigo Hashimoto (Department of Hematology, Faculty of Medicine, Hokkaido University)

Sponsor ONO PHARMACEUTICAL CO., LTD. / Bristol-Myers Squibb K.K.

■MS3-11 Creation of crovalimab by antibody engineering technology

[No.11 Kyoto International Conference Center 1F Room C-1]

Chair Jun-ichi Nishimura (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)

Speaker Tomoyuki Igawa (Chugai Pharmaceutical Co., Ltd.)

Sponsor Chugai Pharmaceutical Co., Ltd.

■MS3-12 Health Care Team in Bispecific Antibody Therapy for Malignant Lymphoma

[No.12 Kyoto International Conference Center 1F Room C-2]

Chair Youko Suehiro (Department of Hematology, National Hospital Organization Kyushu Cancer Center)

Bispecific antibody therapy for malignant lymphoma – Practice and safer operation by health care team –

Speaker Akihiro Tomita (Department of Hematology, Fujita Health University School of Medicine)

Practical Considerations and Tolerability of Bispecific Antibodies for patient care

Speaker Sachie Noda (Outpatient Chemotherapy Center, Nursing Department, Fujita Health University Hospital)

Sponsor Genmab KK, Medical Affairs / AbbVie GK, Medical

MS3-16 Clinical gene panel testing for hematologic malignancies: practical applications and insights

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

- Chair** Seishi Ogawa (Department of Pathology and Tumor Biology, Kyoto University)
Speaker Takahiro Maeda (Division of Precision Medicine, Kyushu University Graduate School of Medical Science)
Sponsor Astellas Pharma Inc. Medical Affairs

MS3-17 Current treatment strategy for Chronic myeloid leukemia

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

- Chair** Shin Fujisawa (Department of Hematology, Yokohama City University Medical Center)
Speaker Hiroshi Ureshino (Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan)
Sponsor Pfizer Japan Inc.

MS3-18 The significance of EZH2 mutation on the pathological findings of follicular lymphoma and the results of 3-year follow-up analysis of tazemetostat phase II study in Japan

[No.18 The Prince Kyoto Takaragaike B2F Gold Room]

- Chair** Hirohiko Shibayama (Department of Hematology, NHO Osaka National Hospital)
The significance of EZH2 mutation on the pathological findings of follicular lymphoma
Speaker Kennosuke Karube (Department of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University)
The results of 3-year follow-up analysis of tazemetostat phase II study in Japan
Speaker Shinya Rai (Department of Hematology and Rheumatology, Kindai University Faculty of Medicine)
Sponsor Medical HQs, Eisai Co., LTD.

12-Oct (Sat) 11 : 20 – 12 : 05

JOLS2-1 Women and Girls with Bleeding Disorders: Hemophilia isn't just for Men!

[Live Streaming Only]

- Chair** Ryosuke Hosokai (Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences)
Speaker Masato Bingo (Department of Laboratory Medicine, Tokyo Medical University)
Sponsor Fujimoto Pharmaceutical Corporation

12-Oct (Sat) 10 : 40—11 : 10

JIS2-2 Remaining clinical challenges in the treatment of PNH Live Recording On-demand

[No.2 Kyoto International Conference Center 2F Room A]

- Chair** Tatsuya Kawaguchi (Department of Medical technology, Kumamoto Health Science University)
- Speaker** Naoshi Obara (Department of Hematology, Faculty of Medicine, University of Tsukuba)
- Sponsor** Medical Affairs Division, Alexion Pharma G.K.

13-Oct (Sun) 11 : 10—11 : 40

**EIS3-2 Blurred Lines:
Navigating the Gray Areas Between Aplastic Anemia and MDS**

[No.2 Kyoto International Conference Center 2F Room A]

- Chair** Kensuke Usuki (Department of Hematology, NTT Medical Center Tokyo)
- 1. Case report from Japan**
- Speaker** Yoshitaka Zaimoku (Department of Hematology, Kanazawa University Hospital, Department of Infection Control and Prevention, Kanazawa University Hospital)
- 2. Case report from Korea**
- Speaker** Jun Ho Jang (Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Republic of Korea)
- Sponsor** Kyowa kirin Co.,Ltd